BioLegend acquires shares of Covance Antibody Services

BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.

The Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection.

These products, including In Vitro Diagnostic (IVD) antibodies for IHC, are well-suited to complement and enhance the current selection of BioLegend research reagents.

Covance Antibody customers can expect the same superior customer support and exceptional value with these products as existing BioLegend customers.

"We are excited to add Covance Antibody's people and products to the BioLegend team," said Gene Lay, President, and CEO, BioLegend.

As neuroinflammation and neurodegeneration become increasingly important topics, Covance Antibody is an ideal strategic fit in BioLegend's commitment to the advancement of discovery in neuroscience.

With the addition of a world-class R&D team and over 600 antibody products for emerging and important targets in this field, BioLegend is positioned to become a leader in neuroscience and immunology research.

The addition of Neuroscience and IHC antibody tools to our catalog means accelerated discovery for our current and new customers. We also hope to bring our well-known quality, support, and value in the Immunology community to Neuroscience researchers worldwide."

Gene Lay, President and CEO, BioLegend



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioLegend. (2019, June 20). BioLegend acquires shares of Covance Antibody Services. News-Medical. Retrieved on June 19, 2024 from

  • MLA

    BioLegend. "BioLegend acquires shares of Covance Antibody Services". News-Medical. 19 June 2024. <>.

  • Chicago

    BioLegend. "BioLegend acquires shares of Covance Antibody Services". News-Medical. (accessed June 19, 2024).

  • Harvard

    BioLegend. 2019. BioLegend acquires shares of Covance Antibody Services. News-Medical, viewed 19 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.